ClinicalTrials.gg
RecruitingNCT04650984FIBROSARCUpdated Apr 8, 2024

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

A Phase 3 interventional study of Onfekafusp alfa and Doxorubicin in Soft Tissue Sarcoma, sponsored by Philogen S.p.A.. Recruiting at 28 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by Philogen S.p.A. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 11 months after the study started (first participant enrolled Nov 2017, registered Nov 2020).
  • Started Nov 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Sarcoma with a site in Germany — 20 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.

Planned enrollment
43rd of 82
102 · median 107
Started
2017
with 8 others
Phase 3
17 of 102
3 open now
Primary completion
2025-12
later than 4 of 29 live
Registered
80th of 102
by date
Lead sponsor
3 of 102
Philogen S.p.A.

Among the 102 studies in Sarcoma with a site in Germany, this one is the 43rd largest by planned enrollment of the 82 interventional ones that give a count, is one of 9 that started in 2017, is one of 17 in phase 3, reaches primary completion later than 4 of the 29 other live ones, and was the 80th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

20 of the 102 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Sarcoma with a site in Germany, or all of them as a file.
02

Study summary

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in advanced or metastatic soft-tissue sarcoma patients.

In the study, 102 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2).

The primary objective of the trial is to evaluate if L19TNF in combination with doxorubicin (Arm 2) given for unresectable or metastatic soft tissue sarcoma improves efficacy measured as progression free survival, as compared to doxorubicin alone (Arm 1).

Read the detailed description

Phase III, open label, randomized, controlled study in subjects with advanced or metastatic soft tissue sarcoma. In the study, 102 patients will be enrolled and parallel assigned in a 1:1 fashion to one of two different arms, as follows:

  • ARM 1: Patients will receive 75 mg/m2 doxorubicin once every 3 weeks (reference treatment).
  • ARM 2: Patients will receive 13 µg/kg L19TNF on days 1, 3 and 5 every 3 weeks in combination with 60 mg/m2 doxorubicin (once every 3 weeks).

Anti-cancer activity will be assessed every 6 weeks during therapy and every 12 weeks thereafter. Median PFS, PFS rates at 3, 6, 9, 12 and 18 months, mOS, OS rate at 12 and 18 months and ORR will be calculated.

Safety assessment will be performed on an ongoing basis during study participation, including standard laboratory assessments. The incidence of AEs will be summarized by severity in all patients with at least one study drug intake.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18-75 years.
  2. Patients must have histological evidence of advanced unresectable and/or high-grade soft tissue sarcoma (grade 2 - 3 according to the FNCLCC grading system) not amenable to curative treatment with surgery or radiotherapy and for which doxorubicin treatment is considered appropriate. Participants with Osteosarcoma, Chondrosarcoma, Ewing Sarcoma/ Primitive Neuroectodermal Tumor (PNET), Kaposi's Sarcoma, Dermatofibrosarcoma protuberans, and Gastrointestinal Stromal Tumors (GIST) will be excluded
  3. Patients must have at least one unidimensionally by computed tomography as defined by criteria 1.1. This lesion should not have been irradiated during previous treatments.
  4. of at least 3 months.
  5. (ECOG) performance status of ≤ 2.
  6. Documented negative test for --. For HBV serology: the determination of HBsAg, anti-HBsAg-Ab and anti-HBCAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  7. Female patients: negative serum pregnancy test at screening for women of (WOCBP)*. WOCBP must agree to use, from the screening to six months following the last administration of L19TNF and/or Doxorubicin, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Male patients: Male subjects able to father children must agree to use two acceptable methods of contraception from the screening to four months following the last administration of L19TNF and/or Doxorubicin (e.g. condom with spermicidal gel). Double-barrier contraception is required.
  8. signed and dated to participate in the study.
  9. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior therapy (except surgery and radiation) for unresectable or malignant soft tissue sarcoma.
  2. Previous treatment with anthracycline-containing chemotherapy.
  3. Radiotherapy within 4 weeks prior to therapy.
  4. Known history of allergy to TNFα, anthracyclines or other intravenously administered human proteins/peptides/antibodies.
  5. Previous therapy with recombinant TNF.
  6. (ANC) \< 1.5 x 109/L, \< 100 x 109/L and (Hb) \< 9.0 g/dl.
  7. Chronically impaired renal function or creatinine ≥ 2.0 x .
  8. Inadequate liver function (, AST, ALP or total ≥ 2.5 x ULN.
  9. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
  10. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  11. Heart insufficiency (> Grade II, (NYHA) criteria).
  12. cardiac arrhythmias or requiring permanent medication.
  13. Uncontrolled hypertension, despite optimal therapy.
  14. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  15. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  16. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of study treatment.
  17. Pregnancy or breast-feeding.
  18. Requirement of chronic administration of or other drugs. Limited use of corticosteroids to treat or prevent acute reactions is not considered an exclusion criterion.
  19. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  20. Known active or latent tuberculosis (TB).
  21. Concurrent other than Soft Tissue Sarcoma, unless the patient has been disease-free for at least 2 years.
  22. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
  23. Serious, non-healing wound, ulcer or bone fracture.
  24. Allergy to study medication or in study medication.
  25. Deep vein thrombosis, pulmonary embolism or other acute vascular events within 6 months.
  26. Anticoagulation therapy with P2Y12 antagonists (e.g., clopidogrel, ticagrelor) and vitamin K antagonists (e.g., phenprocoumon, warfarin).
  27. Concurrent use of other anti-cancer treatments or agents other than study medication.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Active comparator
    Arm 1

    Patients will receive 75 mg/m2 doxorubicin once every 3 weeks (reference treatment).

    Drug: Doxorubicin

  • Experimental
    Arm 2

    Patients will receive 13 µg/kg L19TNF on days 1, 3 and 5 every 3 weeks in combination with 60 mg/m2 doxorubicin (once every 3 weeks).

    Drug: Onfekafusp alfa · Drug: Doxorubicin

Interventions

  • Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.

    Also known as: L19TNF

  • Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.

06

What researchers measure

Primary outcomes

  1. Median Progression free survival (mPFS)

    Progression-free survival PFS in a time-to-event analysis in the L19TNF plus Doxorubicin control group (Arm 2) versus the Doxorubicin alone treatment group (Arm 1).

    Time frame: From randomization up to week 72

Secondary outcomes

  1. PFS rate

    Progression Free Survival

    Time frame: At 3, 6, 9, 12, 18 months after randomization

  2. Overall Response Rate (ORR)

    Rate of Complete Response and Partial Response of L19TNF plus Doxorubicin treatment group (Arm 2) versus Doxorubicin alone (Arm 1).

    Time frame: At 3, 6, 9, 12, 18 months after randomization

  3. Overall survival (OS)

    OS in the L19TNF plus Doxorubicin treatment group (Arm 2) versus Doxorubicin alone (Arm 1)

    Time frame: At 12 months and 18 months after randomization

  4. Median Overall survival (mOS)

    mOS in the L19TNF plus Doxorubicin treatment group (Arm 2) versus Doxorubicin alone (Arm 1).

    Time frame: At 12 months and 18 months after randomization

  5. Adverse Events

    Number of patients with adverse events (AEs) assessed on CTCAE v.4.03

    Time frame: From week 1 up to week 72

  6. HAFA assessment

    Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19TNF (Arm 2).

    Time frame: At day 1 of week 1 and week 2; at day 1 from week 4 up to week 18, every 3 weeks; at week 22-23 (EoT); at week 23-24 (first follow-up visit)

07

Study locations

22 of 28 sites recruiting
  • Institut Bergonié
    Bordeaux, France
    Recruiting
    • Antoine Italiano · Contact
  • Centre Georges François Leclerc
    Dijon, France
    Recruiting
    • Alice Hervieu · Contact
  • Centre Léon Bérard
    Lyon, France
    Recruiting
    • Jean-Yves Blay · Contact
  • Centre Antoine Lacassagne
    Nice, France
    Recruiting
    • Agnès Ducolombier · Contact
  • Institut Claudius Regaud
    Toulouse, France
    Not yet recruiting
    • Thibaud Valentin · Contact
  • Institut Gustave Roussy
    Villejuif, France
    Not yet recruiting
    • Axel Le Cesne · Contact
  • Helios Klinikum Bad Saarow
    Bad Saarow, 15526, Germany
    Recruiting
    • Daniel Pink, Dr · Contact
  • Charité- Universitätsmedizin Berlin
    Berlin, Germany
    Recruiting
    • Anne Floercken, PD Dr. med. · Contact
  • Universitätsklinikum Düsseldorf
    Düsseldorf, Germany
    Not yet recruiting
    • Judith Strapatsas, PD Dr. med. · Contact
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
    Recruiting
    • Marit Ahrens, MD · Contact
  • Universitätsklinik Hamburg-Eppendorf
    Hamburg, Germany
    Recruiting
    • Jana Kaethe Striefler, PD Dr. med. · Contact
  • Heidelberg University Hospital
    Heidelberg, D-69120, Germany
    Recruiting
    • Gerlinde Egerer, MD · Contact
  • Uniklinik Köln
    Köln, 50937, Germany
    Recruiting
    • Roland Ulrich · Contact
  • Universitätsmedizin der J.-G. Universität Mainz
    Mainz, Germany
    Recruiting
    • Marius Fried, PD Dr. · Contact
  • Klinik rechts der Isar
    München,, Germany
    Recruiting
    • Judith Hecker, PD Dr. med · Contact
  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
    Recruiting
    • Christoph Schliemann, Prof. MD · Contact
  • IRCCS Fondazione del Piemonte per l'Oncologia Istituto per la Ricerca e la Cura del Cancro di Candiolo
    Candiolo, Torino, Italy
    Recruiting
    • Sandra Aliberti, Dr. · Contact
  • Bologna University, Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of DIMES
    Bologna, Italy
    Recruiting
    • Emanuela Palmerini, MD · Contact
  • AOU San Luigi Gonzaga
    Orbassano, 10043, Italy
    Not yet recruiting
    • Lorenzo D'Ambrosio, Dr. · Contact
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
    Not yet recruiting
    • Michela Quirino, Dr. · Contact
  • Szpital Pomorski Im. PCK
    Gdynia, Poland
    Not yet recruiting
    • Joanna Pikiel · Contact
  • Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa
    Warsaw, 02-781, Poland
    Recruiting
    • Piotr Rutkowski, MD · Contact
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar, Murcia, Spain
    Recruiting
    • Jeronimo Martinez Garcia, Dr. · Contact
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
    Recruiting
    • Claudia Valverde Morales, Dr. · Contact
  • Hospital Universitario Virgen de las Nieves
    Granada, Spain
    Recruiting
    • Lucía Castillo Portellano · Contact
  • Fundación Jiménez Díaz
    Madrid, 28003, Spain
    Recruiting
    • Javier M Broto, MD · Contact
  • Hospital General Universitario Gregorio Marañón
    Madrid, Spain
    Recruiting
    • Rosa María Álvarez, Dr. · Contact
  • Hospital Miguel Servet
    Zaragoza, Spain
    Recruiting
    • Javier Martinez Trufero, Dr. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Dec 2025, 97 months after the start.

Of 24 phase 3 interventional studies under Sarcoma, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 155. This study's planned 97 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 3, 2020
StartActual
Nov 29, 2017
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04650984
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Nov 29, 2017
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 8, 2024

Study contacts

Teresa Hemmerle, PhD
Contact
regulatory@philogen.com
+39 0577 17816
Marco Taras, Biologist
Contact
regulatory@philogen.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onfekafusp alfa

Start the discussion